Study

Effect of Dupilumab on Onset of Type 1 Disease


Study Dates
2023-06 - Present
Principal Investigator
Spergel, Jonathan
Affiliation
Children's Hospital of Philadelphia
Sponsor Site
Children's Hospital of Philadelphia
PEDSnet Study ID
2023.SPEJ.INST.CHOP.074

Study to determine whether use of the Type 2 blocker dupilumab in children with atopic dermatitis and asthma is associated with increased frequency of developing Type 1 disease.

No files are available for download.

Tags





Funding

This research was made possible through the generous support of Children's Hospital of Philadelphia.

Creative Commons license

a CC-BY 4.0 Attribution license.
Except where otherwised noted, this item's license is described as a CC-BY 4.0 Attribution license.

Publisher

PEDSnet

Project Description

This study investigates whether dupilumab, a Type 2 inflammation-blocking agent commonly used to treat allergic diseases, is associated with an increased risk of developing Type 1 diseases in children. Using the PEDSnet electronic health record network, researchers conducted a multicenter retrospective cohort study involving children aged 6-17 with asthma and/or atopic dermatitis, comparing those treated with dupilumab to those untreated and non-atopic children. The primary outcome was the diagnosis of Type 1 diseases, including conditions affecting the skin, endocrine, gastrointestinal, and other systems.

The results showed that while overall rates of Type 1 disease diagnoses were low, dupilumab-treated children had a 1.9 times higher risk of developing Type 1 diseases within 4 years of treatment. Despite this increased risk, the findings suggest the need for further prospective studies to confirm the accuracy of these diagnoses and better understand the long-term side effects of dupilumab.

Clinical Subject Headings

Parent Partners

Settings

Search Results